Oncology Central

News round-up: Green light from NICE for NSCLC immunotherapy; Pan-Cancer Atlas data and 40 myeloma genes unearthed

0
NICE gives green light to novel immunotherapy for most common lung cancer

Patients with advanced NSCLC, whose disease has progressed following standard chemotherapy, can now access the immunotherapy Tecentriq® (atezolizumab) via the NHS in England and Wales. The novel immunotherapy has significantly extended the lives of patients with advanced NSCLC versus chemotherapy, with fewer side effects.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.